Enovis Holds 2026 Targets as ARVIS Scales-Why This 25% Cash-Flow Bet Matters Now

Enovis is standing behind its 2026 guidance

This is the credibility test.

Last round, Enovis outlined its 2026 plan. This round, management did the harder thing: it reaffirmed full-year 2026 revenue, adjusted EBITDA, adjusted EPS, and free cash flow conversion guidance. Bulls will call that discipline. Bears will say early targets are easiest to defend before execution gets harder.

Why the reaffirmation matters

Enovis posted first-quarter net sales of $589 million, grew 5% on a reported basis and 3% on an organic basis. On the earnings call, management said fewer selling days created roughly a 240-basis-point headwind, and that on a days-adjusted basis, organic growth was 6% at the company level. That makes the quarter look less like a break in the plan and more like a test of how well execution converts when normal timing returns.

That is why the next quarter matters. Reaffirmation turns the 2026 story from aspiration into a deliverables test. If Enovis can grow through product traction while calendar friction fades, investors have a better reason to trust the full-year spread. If not, the market may start to question whether the targets were too aggressive for the underlying business.

The same test applies to cash generation. Enovis is aiming for free cash flow conversion of 25% or higher. That is a meaningful bar, and it matters more than narrative alone.

Recon is doing the heavy lifting while ARVIS builds the path

The more important shift is under the hood. Enovis is no longer asking investors to buy the 2026 story on pure narrative. Recon is producing real growth now, while ARVIS is still building toward a larger payoff.

Recon is the clearest operating signal

At the segment level, Recon grew 11% on a reported basis and 6% on an organic basis, while P&R was flat on a reported basis and 1% on an organic basis. That leaves the debate fairly exposed.

Bulls see what management wants investors to see: a reconstructive business still gaining momentum, helped by recent launches, while the newer innovation stack is still in the investment phase. The proof is already showing up in revenue, not just pipeline talk.

Bears see a narrower growth base. If P&R stays soft, Enovis is leaning more heavily on one lane. That does not break the story, but it does make Recon's execution more important.

The breakdown inside Recon is also useful. U.S. Recon grew 8% organically in the quarter, led by 10% organic growth in extremities. In hips and knees, Enovis grew 6% organically in the U.S., and shoulders delivered double-digit growth, helped by continued traction for ARG. That suggests the business is still executing well inside the core portfolio, not just riding a broad tailwind.

ARVIS is still more wedge than weight

ARVIS is the flashier part of the story, but it is still more strategic optionality than current revenue weight. At launch, it had already completed over 200 cases successfully in the U.S.. That matters because it shows the system is moving past the demo phase and into real operating-room use.

The key point is not that ARVIS alone is expected to change 2026 revenue meaningfully. It is that the system could help Enovis target new customers and strengthen its position in the OR over time. If surgeons adopt the workflow, the upside is deeper penetration and higher implant utilization, not just one product line selling better.

There is a trade-off. Ongoing ARVIS and Nebula rollout means innovation spend stays in play while the mature base still has to carry cash generation. That is the real bull-bear split: bulls accept near-term investment if adoption broadens; bears worry margin can slip before share does.

Free-cash-flow conversion is the clearest test of quality

Revenue growth is only part of the story. Enovis now has to show that growth can turn into cash.

The bullish case is straightforward: Enovis entered the year aiming for free cash flow conversion of 25% or higher, and the company said its first-quarter free cash flow improved year over year. If that trend continues, operating leverage is becoming more than a slogan.

The cautious case is more practical. Investors also have to digest a 420-basis-point tailwind from foreign currency, a 240-basis-point headwind from selling days and a 210-basis-point headwind primarily related to the divestiture of Dr. Comfort. That matters because a target above 25% can look easier when the base is being pushed around by exchange rates, calendar effects, and portfolio changes. Enovis also reported a first-quarter 2026 net loss of $0.15 per share, another reminder that reported earnings are still not telling the full picture.

So the real question is whether operating leverage can hold up under pressure. If currency, selling days, and divestiture effects fade, the path may look cleaner. If not, the 2026 cash target may look more demanding than management's public framing suggests.

What to watch next

• FX normalization: whether the next quarter still benefits from a similar currency tailwind.
• Calendar reset: whether slower growth was mostly a selling-days issue rather than weaker demand.
• Divestiture cleanup: whether the Dr. Comfort headwind fades.
• Cash discipline: whether conversion keeps improving while product rollout spending remains active.

If Enovis clears that bar next quarter, the rest of the 2026 plan becomes easier to underwrite. If not, guidance starts to look more aspirational than execution-backed.

ARVIS adoption is the next rerating hinge

The next rerating hinge is simple: ARVIS has to stop looking like a clean launch and start acting like a sales wedge. Enovis entered the year with stable end markets, and management has framed ARVIS as a tool to target new customers. That only matters if surgeons keep using it after the first cases.

The roadmap from here

Next quarter: prove adoption is real. The signal is not just that ARVIS is in the market. It is that use broadens beyond early adopters, case volume rises, and the workflow fit becomes obvious.

Following quarter: prove it reinforces the core. That means stable end-market commentary again, better quarter-over-quarter execution once calendar effects fade, sustained Recon growth, and cleaner cash conversion behind the 2026 guidance.

What clears the tape

• Broader surgeon uptake and repeat OR use
• Evidence ARVIS reaches new customers, not just existing ones
• Stable end markets and stronger quarter-over-quarter execution
• Free-cash-flow conversion guidance holding as spend stays elevated

What breaks it

• Adoption stays localized or shallow
• No proof the tool helps expand the implant business
• Recon demand cools before cash targets catch up

The market is voting on whether innovation can become predictable revenue and cash this year, not on AR headlines alone.